Exopharm Limited announces Non-Renounceable Pro Rata Rights
Filed with ASX · · 4 pages · English
Entropy Neurodynamics Limited on 6ix
Earlier from Entropy Neurodynamics
- Disclosure Document - Rights Issue Prospectus
- EX1 to Receive $1m from the Issue of Convertible Notes
- EX1 to Receive $0.431m in Prepayment of R&D Tax Incentive
- Appendix 4D and Half Year Report for period 31 December 2022
- Added Funding for 2023
Later from Entropy Neurodynamics
- Results of Non-Renounceable Rights Issue
- EX1 early stage success with in house Elastin (ELN) program
- FY2023 Appendix 4E
- Suspension from Quotation
- Further management changes and cost-reductions
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics